Poseida Therapeutics Appoints Five New Members to Its Gene Therapy Scientific Advisory Board
On March 1, 2023, Poseida Therapeutics (Nasdaq: PSTX) announced the addition of five new members to its Gene Therapy Scientific Advisory Board (SAB), enhancing its expertise in developing innovative gene therapies. The new SAB members include top researchers from global institutions, such as Ian Alexander and Mark Kay. The appointment aims to strengthen the company's gene therapy initiatives targeting rare and life-threatening diseases, including Ornithine Transcarbamylase Deficiency and Hemophilia A. With proprietary technologies like the Cas-CLOVER™ gene editing system, Poseida seeks to pioneer targeted gene therapies that can potentially serve as single treatment cures for these conditions.
- Appointment of five esteemed experts to the Gene Therapy SAB enhances Poseida's R&D capabilities.
- New SAB members bring diverse expertise, potentially improving gene therapy development outcomes.
- Focus on urgent unmet needs in gene therapy for rare diseases may lead to significant market opportunity.
- Dependence on third-party collaborations could pose risks to program advancement.
- Challenges in the gene therapy field may delay or complicate development and approval processes.
SAN DIEGO, March 1, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced the appointment of five new members to its Gene Therapy Scientific Advisory Board (SAB). These world-class researchers will join George M. Church, Ph.D., Chair of Poseida's recently formed Gene Therapy SAB, to provide counsel on the Company's gene therapy programs in development.
The new Gene Therapy SAB members are:
- Ian Alexander, MBBS, Ph.D., Professor of Pediatrics and Molecular Medicine at the University of Sydney, Australia;
- Julian Grünewald, M.D., Assistant Professor at the Technical University of Munich, Germany;
- Mark Kay, M.D., Ph.D., Professor of Pediatrics and Genetics at Stanford University;
- Mark Tracy, Ph.D., President of Tracy BioConsulting, LLC; and
- Kathryn Whitehead, Ph.D., Professor of Chemical Engineering and Biomedical Engineering at Carnegie Mellon University
"We are honored to welcome this world-class group of scientists to join Poseida's Gene Therapy SAB," said Blair Madison, Ph.D., Chief Scientific Officer, Gene Therapy at Poseida. "We have made great strides in our gene therapy programs over the last year and are excited to continue this work in collaboration with this team of experts."
Brent Warner, President of Gene Therapy at Poseida, added: "We are pleased to round out our Gene Therapy SAB as we enter a pivotal moment in the preclinical development of our gene therapy programs for rare diseases with urgent unmet need. We look forward to leveraging the SAB's breadth and depth of expertise and believe that with their guidance, we can be successful in advancing a new class of meaningful and targeted gene therapies."
The Company is currently developing a number of gene therapies addressing rare and life-threatening diseases such as Ornithine Transcarbamylase Deficiency, Hemophilia A and Phenylketonuria, three genetic diseases usually diagnosed early in life. These therapies utilize the Company's proprietary genetic engineering platform technologies, including its Cas-CLOVER™ Site-specific Gene Editing System and piggyBac® DNA Delivery System, in combination with nanoparticle technology, for highly efficient integration that may result in potential single treatment cures.
"The promise of gene therapy and gene editing is emerging as one of the most exciting areas of drug development today," said Dr. Church. "While early successes have been encouraging, the field has been faced with a number of challenges that have limited the number of patients who could benefit from such treatments. However, novel gene therapy approaches, including non-viral gene editing technologies, have the potential to reach unaddressed and underserved patient populations, with the goal of safely and permanently correcting the underlying causes of a wide range of rare diseases."
About Poseida Therapeutics, Inc.
Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated cell and gene therapies with the capacity to cure certain cancers and rare diseases. The Company's pipeline includes allogeneic CAR-T cell therapy product candidates for both solid and liquid tumors as well as in vivo gene therapy product candidates that address patient populations with high unmet medical need. The Company's approach to cell and gene therapies is based on its proprietary genetic editing platforms, including its non-viral piggyBac® DNA Delivery System, Cas-CLOVER™ Site-Specific Gene Editing System and nanoparticle and hybrid gene delivery technologies. The Company has formed global strategic collaborations with Roche and Takeda to unlock the promise of cell and gene therapies for patients. Learn more at www.poseida.com and connect with Poseida on Twitter and LinkedIn.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, expected plans with respect to clinical trials; the potential capabilities and benefits of the Company's technology platforms and product candidates; the Company's plans and strategy with respect to developing its technologies and product candidates; and future contributions of the Company's scientists, partners and collaborators, including members of the Gene Therapy SAB. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the Company's reliance on third parties for various aspects of its business; risks and uncertainties associated with development and regulatory approval of novel product candidates in the biopharmaceutical industry; the Company's ability to retain key scientific or management personnel; the fact that the Company will have limited control over the efforts and resources that its strategic partners devote to advancing development programs under their respective collaboration agreements and the ability of its strategic partners to early terminate the collaborations, such that the Company may not receive the potential fees and payments under the collaboration agreements or fully realize the benefits of such collaborations; and the other risks described in the Company's filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
View original content to download multimedia:https://www.prnewswire.com/news-releases/poseida-therapeutics-appoints-five-new-members-to-its-gene-therapy-scientific-advisory-board-301758574.html
SOURCE Poseida Therapeutics, Inc.
FAQ
What is the recent announcement made by Poseida Therapeutics regarding its Gene Therapy Scientific Advisory Board?
Who are the new members of Poseida Therapeutics' Gene Therapy Scientific Advisory Board?
What diseases is Poseida Therapeutics targeting with its gene therapy programs?
How does Poseida Therapeutics plan to advance its gene therapy initiatives?
What is the significance of the new appointments to Poseida's Gene Therapy SAB?
